Abhinav Aggarwal

Dr. Abhinav Aggarwal

orcid
Yale New Haven Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
SVSwarnima Vardhan
Swarnima Vardhan
AAAbhinav Aggarwal
Abhinav Aggarwal
MVMadhurima Vardhan
Madhurima Vardhan
SDSudhir Diwan
Sudhir Diwan
The dorsal root ganglion (DRG) serves as a pivotal site for managing chronic pain through dorsal root ganglion stimulation (DRG-S). In recent years, the DRG-S has emerged as an attractive modality in the armamentarium of neuromodulation therapy due to its accessibility and efficacy in alleviating chronic pain refractory to conventional treatments. Despite its therapeutic advantages, the precise mechanisms underlying DRG-S-induced analgesia remain elusive, attributed in part to the diverse sensory neuron population within the DRG and its modulation of both peripheral and central sensory processing pathways. Emerging evidence suggests that DRG-S may alleviate pain by several mechanisms, including the reduction of nociceptive signals at the T-junction of sensory neurons, modulation of pain gating pathways within the dorsal horn, and regulation of neuronal excitability within the DRG itself. However, elucidating the full extent of DRG-S mechanisms necessitates further exploration, particularly regarding its supraspinal effects and its interactions with cognitive and affective networks. Understanding these mechanisms is crucial for optimizing neurostimulation technologies and improving clinical outcomes of DRG-S for chronic pain management. This review provides a comprehensive overview of the DRG anatomy, mechanisms of action of the DRG-S, and its significance in neuromodulation therapy for chronic pain.

20 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AAAbhinav Aggarwal
Abhinav Aggarwal
Anton StolearAnton Stolear
Anton Stolear
MAMashiul Alam
Mashiul Alam
SVSwarnima Vardhan
Swarnima Vardhan
MDMaxim Dulgher
Maxim Dulgher
SZStuart W. Zarich
Stuart W. Zarich
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe hereditary arrhythmia syndrome predominantly affecting children and young adults. It manifests through bidirectional or polymorphic ventricular arrhythmia, often culminating in syncope triggered by physical exertion or emotional stress which can lead to sudden cardiac death. Most cases stem from mutations in the gene responsible for encoding the cardiac ryanodine receptor (RyR2), or in the Calsequestrin 2 gene (CASQ2), disrupting the handling of calcium ions within the cardiac myocyte sarcoplasmic reticulum. Diagnosing CPVT typically involves unmasking the arrhythmia through exercise stress testing. This diagnosis emerges in the absence of structural heart disease by cardiac imaging and with a normal baseline electrocardiogram. Traditional first-line treatment primarily involves β-blocker therapy, significantly reducing CPVT-associated mortality. Adjunctive therapies such as moderate exercise training, flecainide, left cardiac sympathetic denervation and implantable cardioverter-defibrillators have been utilized with reasonable success. However, the spectrum of options for managing CPVT has expanded over time, demonstrating decreased rates of arrhythmic events. Furthermore, ongoing research into potential new therapies including gene therapies has the potential to further enhance treatment paradigms. This review aims to succinctly encapsulate the contemporary understanding of the clinical characteristics, diagnostic approach, established therapeutic interventions and the promising future directions in managing CPVT.

19 October 2019 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
SGSaurabh Kumar Gupta
Saurabh Kumar Gupta
AAAbhinav Aggarwal
Abhinav Aggarwal
MSManish Shaw
Manish Shaw
GGGurpreet Singh Gulati
Gurpreet Singh Gulati
SKShyam S Kothari
Shyam S Kothari
RARobert Henry Anderson
Robert Henry Anderson
Aims: Anatomic variations in hearts with common arterial trunk are well-known, although there is no large study of living patients. Detailed knowledge of the origins of the pulmonary and coronary arteries is vital for surgical management. We sought to clarify the variations using computed tomography. Methods and results: We prospectively studied 70 consecutive patients using echocardiography and computed tomography. In 63 (90%) patients, there was aortic dominance, while 7 (10%) had dominance of the pulmonary component. In 27 (43%) patients with aortic dominance, part of the pulmonary segment arose from a truncal valvar sinus. A long confluent pulmonary channel was more common in patients with sinusal origin compared to those with non-sinusal origin of the pulmonary segment (19 vs. 0; P = 0.0005). Close proximity between the orifices of the coronary arteries and the pulmonary component was also more frequent with sinusal origin (21 vs. 6; P < 0.001) with 5 (19%) patients having pulmonary flow obstructed by a truncal valvar leaflet. Conclusion: Sinusal origin of the pulmonary component is common with aortic dominance, frequently in association with a long confluent pulmonary segment, which may be in close proximity to the origin of a coronary artery. One-fifth of patients with sinusal origin of pulmonary component have a truncal valvar leaflet obstructing the pulmonary orifice. These morpho-anatomic findings have important implications for management.

20 November 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
SAShaun Abid
Shaun Abid
AAAbhinav Aggarwal
Abhinav Aggarwal
FDFreddy Duarte
Freddy Duarte
SSSamdish Sethi
Samdish Sethi
SISumedh Iyengar
Sumedh Iyengar
SZStuart Zarich
Stuart Zarich
The rapid rise in nicotine pouch use among teens and young adults signals a shift in nicotine consumption with significant public health implications. Marketed as discreet and “tobacco free,” these products are often perceived as safer alternatives to smoking, yet their cardiovascular risks remain largely unexamined. Emerging concerns center on the high nicotine content, efficient bloodstream delivery, and growing rates of dual or poly-use with other nicotine products. Adolescents, in particular, face heightened vulnerability due to ongoing physiological development and increased addiction susceptibility. This review explores the potential cardiovascular consequences of nicotine pouch use in youth, emphasizing the urgency of evidence-based research to inform clinical guidance, regulatory action, and prevention strategies.

9 May 2025 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
SCSantiago Callegari
Santiago Callegari
GRGaëlle Romain
Gaëlle Romain
AAAbhinav Aggarwal
Abhinav Aggarwal
JCJacob Cleman
Jacob Cleman
KSKim G. Smolderen
Kim G. Smolderen
CMCarlos Mena-Hurtado
Carlos Mena-Hurtado

9 October 2023 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
SJSun-Joo Jang
Sun-Joo Jang
FWFabricio Malaguez Webber
Fabricio Malaguez Webber
MAMashiul Alam
Mashiul Alam
JBJu Young Bae
Ju Young Bae
AAAbhinav Aggarwal
Abhinav Aggarwal
CDCarlos D. Davila
Carlos D. Davila
The role of acute mechanical circulatory support (aMCS) in patients with stress-induced cardiomyopathy (SIC) complicated by cardiogenic shock (CS) is not well studied. Here, we describe the incidence and outcomes of aMCS use in SIC-CS using a large national database. Using the Nationwide Readmissions Database from January 2016 to November 2019, we identified patients hospitalized with SIC who received isolated intra-aortic balloon pump (IABP), microaxial flow pump (Impella, Abiomed), or extracorporeal membrane oxygenation (ECMO) during the index hospitalization. A total of 902 among 94,709 hospitalizations for SIC (1.0%) required aMCS during the index hospitalization: 611 had IABP (67.7%), 189 had Impella (21.0%) and 102 had ECMO (11.3%). Patients with ECMO or Impella had higher in-hospital mortality rates than those with IABP (37.3% vs 29.1% vs 18.5%, respectively). There was an increased adjusted risk of in-hospital death with Impella (adjusted odds ratio [aOR], 1.98; 95% CI, 1.12-3.49) and ECMO (aOR, 4.15; 95% CI, 1.85-9.32) vs IABP. Impella was associated with an increased adjusted risk of 30-day readmission compared to IABP (aOR, 2.53; 95% CI, 1.16-5.51). Patients with ECMO or Impella had a higher incidence of renal replacement therapy and vascular/bleeding complications compared to those who received IABP. In this nationwide analysis using an administrative database, patients who received ECMO and Impella showed higher rates of in-hospital mortality, renal replacement therapy, and vascular/bleeding complications compared to those who received IABP. Patients with more comorbidities may receive more aggressive hemodynamic support which may account for observed mortality differences. Future prospective studies with objective and universal characterization of baseline clinical and hemodynamic characteristics of patients with CS secondary to SIC are needed.